Department of Otorhinolaryngology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.
Eur Arch Otorhinolaryngol. 2024 Jan;281(1):107-116. doi: 10.1007/s00405-023-08097-4. Epub 2023 Jul 1.
Internationally, corticosteroids are still the mainstay treatment for patients with idiopathic sudden sensorineural hearing loss (ISSHL). This is a retrospective monocentric study investing the impact of adding N-acetylcysteine (NAC) to prednisolone treatment on patients with ISSHL at a tertiary university otorhinolaryngology department.
793 patients (median age 60 years; 50.9% women) with a new diagnosis of ISSHL from 2009 to 2015 were included in the study. 663 patients received NAC administration in addition to standard tapered prednisolone treatment. Univariate and multivariable analysis were performed to identify independent factors regarding negative prognosis of hearing recovery.
Mean initial ISSHL and hearing gain after treatment in 10-tone pure tone audiometry (PTA) were 54.8 ± 34.5 dB and 15.2 ± 21.2 dB, respectively. In univariate analysis, treatment with prednisolone and NAC was associated with a positive prognosis of hearing recovery in the Japan classification in 10-tone PTA. In multivariable analysis on Japan classification in 10-tone PTA including all significant factors from univariate analysis, negative prognosis of hearing recovery were age > median (odds ratio [OR] 1.648; 95% confidence interval [CI] 1.139-2.385; p = 0.008), diseased opposite ear (OR 3.049; CI 2.157-4.310; p < 0.001), pantonal ISSHL (OR 1.891; CI 1.309-2.732; p = 0.001) and prednisolone alone without NAC treatment (OR 1.862; CI 1.200-2.887; p = 0.005).
Prednisolone treatment combined with NAC resulted in better hearing outcomes in patients with ISSHL than treatment without NAC.
国际上,皮质类固醇仍然是特发性突发性聋(ISSHL)患者的主要治疗方法。这是一项回顾性单中心研究,调查了在一所三级大学耳鼻喉科,在泼尼松龙治疗中加入 N-乙酰半胱氨酸(NAC)对 ISSHL 患者的影响。
2009 年至 2015 年间,共有 793 例新发 ISSHL 患者纳入本研究。663 例患者接受 NAC 治疗,同时接受标准递减泼尼松龙治疗。采用单因素和多因素分析确定听力恢复不良的独立预后因素。
10 音纯音听阈(PTA)平均初始 ISSHL 和治疗后听力增益分别为 54.8±34.5dB 和 15.2±21.2dB。单因素分析显示,在 10 音 PTA 的日本分类中,泼尼松龙和 NAC 联合治疗与听力恢复的良好预后相关。在包括单因素分析中所有显著因素的 10 音 PTA 日本分类的多因素分析中,听力恢复不良的预后因素为年龄>中位数(比值比 [OR] 1.648;95%置信区间 [CI] 1.139-2.385;p=0.008)、对侧患病耳(OR 3.049;CI 2.157-4.310;p<0.001)、泛音 ISSHL(OR 1.891;CI 1.309-2.732;p=0.001)和单独使用泼尼松龙而不使用 NAC 治疗(OR 1.862;CI 1.200-2.887;p=0.005)。
与不使用 NAC 的治疗相比,泼尼松龙联合 NAC 治疗可改善 ISSHL 患者的听力结果。